|Dr. Keelung Hong||Founder, Chairman & CEO||N/A||N/A||1943|
|Mr. Zhi-Hong Yeh M.B.A.||Pres||N/A||N/A||1972|
|Ms. Ru-Yun Lin M.B.A.||CFO and VP of Fin. & Admin.||N/A||N/A||1966|
|Dr. Wenji Chen M.B.A., Ph.D.||VP of Corp. Devel. Division||N/A||N/A||1959|
|Dr. Luke Guo Ph.D.||Chief Scientific Advisor & Member of Scientific Advisory Board||N/A||N/A||N/A|
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. The company provides various product candidates that target various areas of unmet medical need in pain management, ophthalmology, and oncology. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP) for knee osteoarthritis pain. The company's product candidates also comprises TLC590, a non-opioid BioSeizer formulation of the API ropivacaine for post-surgical pain management; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP for ophthalmology indications; and TLC178, an API to treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei City, Taiwan with additional offices in Hsinchu, Hong Kong, Leiden, Melbourne, Shanghai, South San Francisco, and Tokyo.
Taiwan Liposome Company, Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.